Table 1. Median Inhibitory Concentration (IC₅₀) and Average IC₅₀ (GI₅₀) of Each Compound against the Four Cancer Cell Lines.

comp	cell viability %	cytotoxic activity IC50 ± SEM (nM)
		A-549	MCF-7	Panc-1	HT-29	average (GI50)
4	91	47 ± 4	50 ± 5	48 ± 4	49 ± 4	49
5	89	67 ± 6	71 ± 6	68 ± 6	70 ± 6	68
6	90	42 ± 4	46 ± 4	44 ± 4	47 ± 4	45
7	93	70 ± 7	74 ± 7	72 ± 7	73 ± 7	71
8	92	64 ± 6	68 ± 6	67 ± 6	68 ± 6	67
9	90	74 ± 7	79 ± 7	75 ± 7	77 ± 7	76
10	89	52 ± 5	55 ± 5	52 ± 5	54 ± 5	53
11	92	56 ± 5	58 ± 5	56 ± 5	59 ± 5	57
12	87	36 ± 3	38 ± 3	36 ± 3	38 ± 3	37
13	90	62 ± 6	64 ± 6	61 ± 6	64 ± 6	62
14	89	40 ± 4	44 ± 4	42 ± 4	43 ± 4	41
15	91	33 ± 3	36 ± 3	34 ± 3	36 ± 3	35
erlotinib	ND	30 ± 3	40 ± 3	30 ± 3	30 ± 3	33